Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market 2022 by Company, Regions, Type and Application, Forecast to 2028

  • receipt Report ID : 324530
  • calendar_today Published On: Jan, 2023
  • file_copy Pages: 165
  • list Pharmaceuticals and Healthcare
Buy @ $3500

The Gastroesophageal Reflux Disease (GERD) Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest study, due to COVID-19 pandemic, the global Gastroesophageal Reflux Disease (GERD) Therapeutics market size is estimated to be worth US$ 4940.8 million in 2021 and is forecast to a readjusted size of USD 4440.9 million by 2028 with a CAGR of -1.5% during review period. Heartburn accounting for % of the Gastroesophageal Reflux Disease (GERD) Therapeutics global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Antacids segment is altered to a % CAGR between 2022 and 2028.

Global key companies of Gastroesophageal Reflux Disease (GERD) Therapeutics include AstraZeneca, Eisai, GSK, Takeda, and Johnson & Johnson, etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation

Gastroesophageal Reflux Disease (GERD) Therapeutics market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

Antacids

Pro-kinetic agents

H2 Receptor Blockers

Proton Pump Inhibitors (PPIs)

Market segment by Application, can be divided into

Heartburn

Acid reflux disorders

Market segment by players, this report covers

AstraZeneca

Eisai

GSK

Takeda

Johnson & Johnson

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:

Chapter 1, to describe Gastroesophageal Reflux Disease (GERD) Therapeutics product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top players of Gastroesophageal Reflux Disease (GERD) Therapeutics, with revenue, gross margin and global market share of Gastroesophageal Reflux Disease (GERD) Therapeutics from 2019 to 2022.

Chapter 3, the Gastroesophageal Reflux Disease (GERD) Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Gastroesophageal Reflux Disease (GERD) Therapeutics market forecast, by regions, type and application, with revenue, from 2023 to 2028.

Chapter 11 and 12, to describe Gastroesophageal Reflux Disease (GERD) Therapeutics research findings and conclusion, appendix and data source.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Product Overview and Scope of Gastroesophageal Reflux Disease (GERD) Therapeutics

1.2 Classification of Gastroesophageal Reflux Disease (GERD) Therapeutics by Type

1.2.1 Overview: Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Type: 2017 Versus 2021 Versus 2028

1.2.2 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share by Type in 2021

1.2.3 Antacids

1.2.4 Pro-kinetic agents

1.2.5 H2 Receptor Blockers

1.2.6 Proton Pump Inhibitors (PPIs)

1.3 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market by Application

1.3.1 Overview: Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Application: 2017 Versus 2021 Versus 2028

1.3.2 Heartburn

1.3.3 Acid reflux disorders

1.4 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size & Forecast

1.5 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size and Forecast by Region

1.5.1 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Region: 2017 VS 2021 VS 2028

1.5.2 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Region, (2017-2022)

1.5.3 North America Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size and Prospect (2017-2028)

1.5.4 Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size and Prospect (2017-2028)

1.5.5 Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size and Prospect (2017-2028)

1.5.6 South America Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size and Prospect (2017-2028)

1.5.7 Middle East and Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size and Prospect (2017-2028)

1.6 Market Drivers, Restraints and Trends

1.6.1 Gastroesophageal Reflux Disease (GERD) Therapeutics Market Drivers

1.6.2 Gastroesophageal Reflux Disease (GERD) Therapeutics Market Restraints

1.6.3 Gastroesophageal Reflux Disease (GERD) Therapeutics Trends Analysis

2 Company Profiles

2.1 AstraZeneca

2.1.1 AstraZeneca Details

2.1.2 AstraZeneca Major Business

2.1.3 AstraZeneca Gastroesophageal Reflux Disease (GERD) Therapeutics Product and Solutions

2.1.4 AstraZeneca Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.1.5 AstraZeneca Recent Developments and Future Plans

2.2 Eisai

2.2.1 Eisai Details

2.2.2 Eisai Major Business

2.2.3 Eisai Gastroesophageal Reflux Disease (GERD) Therapeutics Product and Solutions

2.2.4 Eisai Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2.5 Eisai Recent Developments and Future Plans

2.3 GSK

2.3.1 GSK Details

2.3.2 GSK Major Business

2.3.3 GSK Gastroesophageal Reflux Disease (GERD) Therapeutics Product and Solutions

2.3.4 GSK Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3.5 GSK Recent Developments and Future Plans

2.4 Takeda

2.4.1 Takeda Details

2.4.2 Takeda Major Business

2.4.3 Takeda Gastroesophageal Reflux Disease (GERD) Therapeutics Product and Solutions

2.4.4 Takeda Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4.5 Takeda Recent Developments and Future Plans

2.5 Johnson & Johnson

2.5.1 Johnson & Johnson Details

2.5.2 Johnson & Johnson Major Business

2.5.3 Johnson & Johnson Gastroesophageal Reflux Disease (GERD) Therapeutics Product and Solutions

2.5.4 Johnson & Johnson Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5.5 Johnson & Johnson Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Share by Players (2019, 2020, 2021, and 2022)

3.2 Market Concentration Rate

3.2.1 Top 3 Gastroesophageal Reflux Disease (GERD) Therapeutics Players Market Share in 2021

3.2.2 Top 10 Gastroesophageal Reflux Disease (GERD) Therapeutics Players Market Share in 2021

3.2.3 Market Competition Trend

3.3 Gastroesophageal Reflux Disease (GERD) Therapeutics Players Head Office, Products and Services Provided

3.4 Gastroesophageal Reflux Disease (GERD) Therapeutics Mergers & Acquisitions

3.5 Gastroesophageal Reflux Disease (GERD) Therapeutics New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Market Share by Type (2017-2022)

4.2 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Forecast by Type (2023-2028)

5 Market Size Segment by Application

5.1 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share by Application (2017-2022)

5.2 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application

6.1 North America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Type (2017-2028)

6.2 North America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Application (2017-2028)

6.3 North America Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Country

6.3.1 North America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Country (2017-2028)

6.3.2 United States Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size and Forecast (2017-2028)

6.3.3 Canada Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size and Forecast (2017-2028)

6.3.4 Mexico Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application

7.1 Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Type (2017-2028)

7.2 Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Application (2017-2028)

7.3 Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Country

7.3.1 Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Country (2017-2028)

7.3.2 Germany Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size and Forecast (2017-2028)

7.3.3 France Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size and Forecast (2017-2028)

7.3.4 United Kingdom Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size and Forecast (2017-2028)

7.3.5 Russia Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size and Forecast (2017-2028)

7.3.6 Italy Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Type (2017-2028)

8.2 Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Application (2017-2028)

8.3 Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Region

8.3.1 Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Region (2017-2028)

8.3.2 China Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size and Forecast (2017-2028)

8.3.3 Japan Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size and Forecast (2017-2028)

8.3.4 South Korea Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size and Forecast (2017-2028)

8.3.5 India Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size and Forecast (2017-2028)

8.3.6 Southeast Asia Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size and Forecast (2017-2028)

8.3.7 Australia Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application

9.1 South America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Type (2017-2028)

9.2 South America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Application (2017-2028)

9.3 South America Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Country

9.3.1 South America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Country (2017-2028)

9.3.2 Brazil Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size and Forecast (2017-2028)

9.3.3 Argentina Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Type (2017-2028)

10.2 Middle East & Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Application (2017-2028)

10.3 Middle East & Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Country

10.3.1 Middle East & Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Country (2017-2028)

10.3.2 Turkey Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size and Forecast (2017-2028)

10.3.3 Saudi Arabia Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size and Forecast (2017-2028)

10.3.4 UAE Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Type, (USD Million), 2017 VS 2021 VS 2028

Table 2. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Application, (USD Million), 2017 VS 2021 VS 2028

Table 3. Global Market Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)

Table 4. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (USD Million) by Region (2017-2022)

Table 5. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share by Region (2023-2028)

Table 6. AstraZeneca Corporate Information, Head Office, and Major Competitors

Table 7. AstraZeneca Major Business

Table 8. AstraZeneca Gastroesophageal Reflux Disease (GERD) Therapeutics Product and Solutions

Table 9. AstraZeneca Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 10. Eisai Corporate Information, Head Office, and Major Competitors

Table 11. Eisai Major Business

Table 12. Eisai Gastroesophageal Reflux Disease (GERD) Therapeutics Product and Solutions

Table 13. Eisai Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 14. GSK Corporate Information, Head Office, and Major Competitors

Table 15. GSK Major Business

Table 16. GSK Gastroesophageal Reflux Disease (GERD) Therapeutics Product and Solutions

Table 17. GSK Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 18. Takeda Corporate Information, Head Office, and Major Competitors

Table 19. Takeda Major Business

Table 20. Takeda Gastroesophageal Reflux Disease (GERD) Therapeutics Product and Solutions

Table 21. Takeda Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 22. Johnson & Johnson Corporate Information, Head Office, and Major Competitors

Table 23. Johnson & Johnson Major Business

Table 24. Johnson & Johnson Gastroesophageal Reflux Disease (GERD) Therapeutics Product and Solutions

Table 25. Johnson & Johnson Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 26. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)

Table 27. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Share by Players (2019, 2020, 2021, and 2022)

Table 28. Breakdown of Gastroesophageal Reflux Disease (GERD) Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)

Table 29. Gastroesophageal Reflux Disease (GERD) Therapeutics Players Head Office, Products and Services Provided

Table 30. Gastroesophageal Reflux Disease (GERD) Therapeutics Mergers & Acquisitions in the Past Five Years

Table 31. Gastroesophageal Reflux Disease (GERD) Therapeutics New Entrants and Expansion Plans

Table 32. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (USD Million) by Type (2017-2022)

Table 33. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Share by Type (2017-2022)

Table 34. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Forecast by Type (2023-2028)

Table 35. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Application (2017-2022)

Table 36. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Forecast by Application (2023-2028)

Table 37. North America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Type (2017-2022) & (USD Million)

Table 38. North America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Type (2023-2028) & (USD Million)

Table 39. North America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Application (2017-2022) & (USD Million)

Table 40. North America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Application (2023-2028) & (USD Million)

Table 41. North America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Country (2017-2022) & (USD Million)

Table 42. North America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Country (2023-2028) & (USD Million)

Table 43. Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Type (2017-2022) & (USD Million)

Table 44. Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Type (2023-2028) & (USD Million)

Table 45. Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Application (2017-2022) & (USD Million)

Table 46. Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Application (2023-2028) & (USD Million)

Table 47. Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Country (2017-2022) & (USD Million)

Table 48. Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Country (2023-2028) & (USD Million)

Table 49. Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Type (2017-2022) & (USD Million)

Table 50. Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Type (2023-2028) & (USD Million)

Table 51. Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Application (2017-2022) & (USD Million)

Table 52. Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Application (2023-2028) & (USD Million)

Table 53. Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Region (2017-2022) & (USD Million)

Table 54. Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Region (2023-2028) & (USD Million)

Table 55. South America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Type (2017-2022) & (USD Million)

Table 56. South America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Type (2023-2028) & (USD Million)

Table 57. South America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Application (2017-2022) & (USD Million)

Table 58. South America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Application (2023-2028) & (USD Million)

Table 59. South America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Country (2017-2022) & (USD Million)

Table 60. South America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Country (2023-2028) & (USD Million)

Table 61. Middle East & Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Type (2017-2022) & (USD Million)

Table 62. Middle East & Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Type (2023-2028) & (USD Million)

Table 63. Middle East & Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Application (2017-2022) & (USD Million)

Table 64. Middle East & Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Application (2023-2028) & (USD Million)

Table 65. Middle East & Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Country (2017-2022) & (USD Million)

Table 66. Middle East & Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Country (2023-2028) & (USD Million)

List of Figures

Figure 1. Gastroesophageal Reflux Disease (GERD) Therapeutics Picture

Figure 2. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share by Type in 2021

Figure 3. Antacids

Figure 4. Pro-kinetic agents

Figure 5. H2 Receptor Blockers

Figure 6. Proton Pump Inhibitors (PPIs)

Figure 7. Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share by Application in 2021

Figure 8. Heartburn Picture

Figure 9. Acid reflux disorders Picture

Figure 10. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size, (USD Million): 2017 VS 2021 VS 2028

Figure 11. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Forecast (2017-2028) & (USD Million)

Figure 12. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share by Region (2017-2028)

Figure 13. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share by Region in 2021

Figure 14. North America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)

Figure 15. Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)

Figure 16. Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)

Figure 17. South America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)

Figure 18. Middle East and Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)

Figure 19. Gastroesophageal Reflux Disease (GERD) Therapeutics Market Drivers

Figure 20. Gastroesophageal Reflux Disease (GERD) Therapeutics Market Restraints

Figure 21. Gastroesophageal Reflux Disease (GERD) Therapeutics Market Trends

Figure 22. AstraZeneca Recent Developments and Future Plans

Figure 23. Eisai Recent Developments and Future Plans

Figure 24. GSK Recent Developments and Future Plans

Figure 25. Takeda Recent Developments and Future Plans

Figure 26. Johnson & Johnson Recent Developments and Future Plans

Figure 27. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Share by Players in 2021

Figure 28. Gastroesophageal Reflux Disease (GERD) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021

Figure 29. Global Top 3 Players Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share in 2021

Figure 30. Global Top 10 Players Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share in 2021

Figure 31. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)

Figure 32. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Share by Type in 2021

Figure 33. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Share Forecast by Type (2023-2028)

Figure 34. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Share by Application in 2021

Figure 35. Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Share Forecast by Application (2023-2028)

Figure 36. North America Gastroesophageal Reflux Disease (GERD) Therapeutics Sales Market Share by Type (2017-2028)

Figure 37. North America Gastroesophageal Reflux Disease (GERD) Therapeutics Sales Market Share by Application (2017-2028)

Figure 38. North America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share by Country (2017-2028)

Figure 39. United States Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 40. Canada Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 41. Mexico Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 42. Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Sales Market Share by Type (2017-2028)

Figure 43. Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Sales Market Share by Application (2017-2028)

Figure 44. Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share by Country (2017-2028)

Figure 45. Germany Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 46. France Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 47. United Kingdom Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 48. Russia Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 49. Italy Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 50. Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Sales Market Share by Type (2017-2028)

Figure 51. Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Sales Market Share by Application (2017-2028)

Figure 52. Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share by Region (2017-2028)

Figure 53. China Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 54. Japan Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 55. South Korea Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 56. India Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 57. Southeast Asia Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 58. Australia Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 59. South America Gastroesophageal Reflux Disease (GERD) Therapeutics Sales Market Share by Type (2017-2028)

Figure 60. South America Gastroesophageal Reflux Disease (GERD) Therapeutics Sales Market Share by Application (2017-2028)

Figure 61. South America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share by Country (2017-2028)

Figure 62. Brazil Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 63. Argentina Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 64. Middle East and Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Sales Market Share by Type (2017-2028)

Figure 65. Middle East and Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Sales Market Share by Application (2017-2028)

Figure 66. Middle East and Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share by Country (2017-2028)

Figure 67. Turkey Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 68. Saudi Arabia Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 69. UAE Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 70. Methodology

Figure 71. Research Process and Data Source

shopping_cart License Type

Buy Now

email Quick Contact

tag_faces Our Clients

help Need Help?

Please contact directly on our US and India numbers

+1-201-465-4211

Please feel free to write an email to us or to use our electronic ticketing system.

sales@marketsandresearch.biz